Etrolizumab - Genentech

Drug Profile

Etrolizumab - Genentech

Alternative Names: Monoclonal antibody beta7; PRO145223; recombinant-human-monoclonal-antibody-beta7; RG 7413; rhu-monoclonal-antibody-beta7; rhuMAb Beta7; rhuMAb β7; RO 5490261

Latest Information Update: 27 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Antiulcers; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Integrin alphaEbeta7 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 09 Apr 2018 Genentech completes a phase I trial in Healthy volunteers in USA (SC) (NCT02996019)
  • 13 Mar 2018 Phase-I clinical trials in Crohn's disease (In children, In adolescents) in Spain, Poland (SC) (NCT03478956) (EudraCT2017-003649-10)
  • 13 Mar 2018 Phase-I clinical trials in Ulcerative colitis (In adolescents, In children) in Spain, Poland (SC) (NCT03478956) (EudraCT2017-003649-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top